Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN

In SERAPHIN, a long-term, randomised, controlled trial (NCT00660179) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-naïve inci...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Respir J
Main Authors: Simonneau, Gérald, Channick, Richard N., Delcroix, Marion, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Jansa, Pavel, Le Brun, Franck-Olivier, Mehta, Sanjay, Perchenet, Loic, Pulido, Tomás, Sastry, B.K.S., Sitbon, Olivier, Souza, Rogério, Torbicki, Adam, Rubin, Lewis J.
Formato: Artigo
Idioma:Inglês
Publicado em: European Respiratory Society 2015
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4664609/
https://ncbi.nlm.nih.gov/pubmed/26493786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.00364-2015
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados